Positioning checkpoint blockade in urothelial cancer: PURE-01 and PEANUTS
- PMID: 33068729
- DOI: 10.1016/j.annonc.2020.10.468
Positioning checkpoint blockade in urothelial cancer: PURE-01 and PEANUTS
Conflict of interest statement
Disclosure ML has received educational grants from BMS, AstraZeneca, Shionogi, and Sanofi and consulting fees or travel support from Janssen, BMS, MSD, Bayer, BioNTech, Shionogi, Pfizer, and Astra Zeneca. AL has declared no conflicts of interest.
Comment on
-
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆.Ann Oncol. 2020 Dec;31(12):1755-1763. doi: 10.1016/j.annonc.2020.09.011. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979511
-
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979512 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources